Skip to content Skip to footer
Subscribe Now
Insights+ Key Biosimilars Events of April 2022
INSIGHTS+
Insights+ Key Biosimilars Events of April 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of April, Alvotech resolved a European patent dispute with…
May 5, 20220Comments
PharmaShots Interview GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma
VIEWPOINTS
PharmaShots Interview: GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma
In an interview with PharmaShots, Tom Corbridge, Senior Medical Lead at GSK shared his views on the approval of its anti-IL-5 biologic NUCALA (mepolizumab) in a 40 mg pre-filled syringe for appropriate children aged 6 to 11 years old with severe eosinophilic asthma (SEA)Shots:Nucala can now be given by a child’s HCPs or administered…
May 4, 20220Comments
PharmaShots Interview X4 Pharmaceuticals’ Paula Ragan Shares Insights on Mavorixafor for the Treatment of Multiple Immunodeficiencies
VIEWPOINTS
PharmaShots Interview: X4 Pharmaceuticals’ Paula Ragan Shares Insights on Mavorixafor for the Treatment of Multiple Immunodeficiencies
In an interview with PharmaShots, Paula Ragan, Ph.D., CEO, and President at X4 Pharmaceuticals shared her views on the data of Mavorixafor which showed increased immune cell levels regardless of patients having a CXCR4 mutation to treat multiple immunodeficiencies, presented at ASH 2021Shots:The ongoing long-term extension arm of the P-II trial evaluates Mavorixafor (CXCR4 antagonist) in patients with WHIM syndrome. The therapy continues…
May 3, 20220Comments
PharmaShots Interview Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma
VIEWPOINTS
PharmaShots Interview: Janssen’s Mark Wildgust Shares Insights on Imbruvica for Chronic Lymphocytic Leukemia and Darzalex for Multiple Myeloma
In an interview with PharmaShots, Mark Wildgust, Vice President, Global Medical Affairs, Oncology at Janssen shared his views on the data of Imbruvica in P-III (GLOW) and P-II (CAPTIVATE) studies for the treatment of CLL or SLL and also highlighted the results of Darzalex in the P-II (GRIFFIN) & P-III (MAIA) study for multiple myelomaThe P-III (GLOW) and P-II (CAPTIVATE) studies evaluating Imbruvica + venetoclax (I+V) as a…
May 2, 20220Comments
PharmaShots Interview Pierre Fabre’ Roberta Valenti Shares Insights on Nerlynx (neratinib) for the Treatment of HER2 Early Breast Cancer
VIEWPOINTS
PharmaShots Interview: Pierre Fabre’ Roberta Valenti Shares Insights on Nerlynx (neratinib) for the Treatment of HER2 Early Breast Cancer
In an interview with PharmaShots, Roberta Valenti, Global Medical Director at Pierre Fabre shared her views on Nerlynx (neratinib) in P-II (CONTROL) study & showed improved tolerability with all the investigated diarrhoea prophylaxis strategies, presented at SABCS 2021Shots:The P-II (CONTROL) study evaluates 6 preventive antidiarrheal prophylaxis options with loperamide for the prevention of neratinib-associated diarrhoea. Patients will receive neratinib (240 mg/day) for 1yr.…
April 27, 20220Comments
PharmaShots Interview ViiV Healthcare’s Kimberly Smith Shares Insights on Apretude for the Prevention of HIV
VIEWPOINTS
PharmaShots Interview: ViiV Healthcare’s Kimberly Smith Shares Insights on Apretude for the Prevention of HIV
In an interview with PharmaShots, Kimberly Smith, Senior Vice President, Head of Research & Development at ViiV Healthcare shared her views on the US FDA’s approval of the first long-acting injectable option of Apretude for the prevention of HIVThe approval is based on the P-IIb/III (HPTN 083/084) trial to evaluate cabotegravir (q8w) vs FTC/TDF (200/300 mg) in 7,700+ patients who…
April 26, 20220Comments
PharmaShots Interview Janssen’s Soumya D. Chakravarty Shares Insights on Tremfya (guselkumab) for the Treatment of Active Psoriatic Arthritis
VIEWPOINTS
PharmaShots Interview: Janssen’s Soumya D. Chakravarty Shares Insights on Tremfya (guselkumab) for the Treatment of Active Psoriatic Arthritis
In an interview with PharmaShots, Soumya D. Chakravarty, Senior Director, Strategic Lead, Rheumatology Therapeutic Area at Janssen shared his views on the data of Tremfya in the P-IIIb (COSMOS) trial for the treatment of active psoriatic arthritis, published in the Annals of the Rheumatic DiseasesThe P-IIIb (COSMOS) trial evaluates Tremfya (100mg) vs PBO in a ratio (2:1) in 285 patients with active PsA…
April 25, 20220Comments